Hormone Replacement Therapy in the Geriatric Patient: Current State of the Evidence and Questions for the Future-Estrogen, Progesterone, Testosterone, and Thyroid Hormone Augmentation in Geriatric Clinical Practice: Part 2

Clinics in Geriatric Medicine

Volumn 27, Issue 4, 2011, Pages 561-575

  Schwartz, Erika ^a   Morelli, Vincent ^b   Holtorf, Kent ^c  

^a Age Management Institute   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

^c Holtorf Medical Group   (United States)

Author keywords

Elderly; Frailty; Hormone replacement therapy; Hypothyroidism; T 3; T 4; Testosterone; Thyroid hormone

Indexed keywords

BOLDENONE UNDECENOATE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; LIOTHYRONINE SODIUM; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROID HORMONE; THYROTROPIN; THYROXINE;

ACNE; ACUTE CORONARY SYNDROME; ANDROPAUSE; BLOOD PRESSURE; BONE DENSITY; BONE MASS; CANCER RISK; CEREBROVASCULAR ACCIDENT; COGNITION; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; FATIGUE; FRAIL ELDERLY; GERIATRIC PATIENT; GYNECOMASTIA; HEART DISEASE; HEART INFARCTION; HEMATOCRIT; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPOGONADISM; HYPOTHYROIDISM; LEAN BODY WEIGHT; LIOTHYRONINE BLOOD LEVEL; LIVER CANCER; LIVER CYST; LIVER FAILURE; MORTALITY; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; POLYCYTHEMIA; PROSTATE CANCER; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; WEIGHT GAIN;

AGING; ESTROGENS; GERIATRICS; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTERONE; PROGNOSIS; QUESTIONNAIRES; TESTOSTERONE; THYROID HORMONES;

EID: 80555144123     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2011.07.004     Document Type: Review

References (105)

1. Brown-Séquard C.E. The effects produced on man by subcutaneous injection of a liquid obtained from the testicles of animals. Lancet 1889, 137:105-107.
2. Dickinson P., Zinneman H.H., Swaim W.R., et al. Effects of testosterone treatment on plasma proteins and amino acids in men. J Clin Endocrinol Metab 1969, 29:837-841.
3. Sorva R., Kuusi T., Taskinen M.R., et al. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988, 69:191-197.
4. Kasperk C.H., Wergedal J.E., Farley J.R., et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989, 124:1576-1578.
5. Gardner F.H., Nathan D.G., Piomelli S., et al. The erythrocythaemiceffects of androgens. Br J Haematol 1968, 14:611-615.
6. Feldman H.A., Longcope C., Derby C.A., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002, 87:589-598.
7. Mulligan T., Frick M., Zuraw Q., et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006, 60:762-769.
8. Winters J. Current status of testosterone replacement therapy in men. Arch Fam Med 1999, 8:257-263.
9. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26:833-876.
10. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295:1288-1299.
11. Selvin E., Feinleib M., Zhang L., et al. Androgens and diabetes in men: results from the third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007, 30:234-238.
12. Stellato R.K., Feldman H.A., Hamdy O., et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000, 23:490-494.
13. Laaksonen D.E., Niskanen L., Punnonen K., et al. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27:1036-1041.
14. Shores M.M., Matsumoto A.M., Sloan K.L., et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006, 166:1660-1665.
15. Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007, 116:2694-2701.
16. Wald M., Meacham R.B., Ross L.S., et al. Testosterone replacement therapy for older men. J Androl 2006, 27:126-132.
17. Matsumoto A.M. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994, 23:857-875.
18. Gruenewald D.A., Matsumoto A.M. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003, 51:101-115.
19. Blum J., Harris R.H. Diagnosis and treatment of hypogonadism with emphasis on erectile dysfunction and osteoporosis. Prim Care Case Reviews 2003, 6:97-109.
20. Basaria S., Dobs A.S. Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001, 110:563-572.
21. Bhasin S., Bagatell C.J., Bremner W.J., et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998, 83:3435-3448.
22. Carruthers M., Trinick T.R., Wheeler M.J. The validity of androgen assays. The Aging Male 2007, 10:165-172.
23. Wheeler M.J., Barnes S.C. Measurement of testosterone in the diagnosis of hypogonadism in the ageing male. Clin Endocrinol (Oxf) 2008, 69:515-525.
24. Lazarou R., Reyes-Vallejo L., Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med 2006, 3:1085-1089.
25. Morgentaler A. Commentary: guidelines for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab 2007, 92:416-417.
26. English K.M., Steeds R.P., Jones H.T., et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind placebo-controlled study. Circulation 2000, 102:1906-1911.
27. Rosano G.M., Leonardo F., Pagnotta P., et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999, 99:1666-1670.
28. Webb C.M., Adamson D.L., de Zeigler D., et al. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999, 83:437-439.
29. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-M156.
30. Conroy S. Defining frailty: the holy grail of geriatric medicine. J Nutr Health Aging 2009, 13:389.
31. Kenny A.M., Kleppinger A., Annis K., et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010, 58:1134-1143.
32. Srinivas-Shankar U., Roberts S.A., Connolly M.J., et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
33. Page S.T., Amory J.K., Bowman F.D., et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005, 90:1502-1510.
34. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999, 84:2647-2653.
35. Clague J.E., Wu F.C., Horan M.A. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl 1999, 22:261-265.
36. Wittert G.A., Chapman I.M., Haren M.T., et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003, 58:618-625.
37. Brill K.T., Weltman A.L., Gentili A., et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002, 87:5649-5657.
38. Nair K.S., Rizza R.A., O'Brien P., et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355:1647-1659.
39. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
40. Barrett-Conner E., Von Muhlen D.G., Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999, 84:573-577.
41. Zarrouf F.A., Artz S., Griffith J., et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009, 15:289-305.
42. Pope H.G., Amiaz R., Brennan B.P., et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol 2010, 30:126-134.
43. Barrett-Connor E., Goodman-Gruen D., Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999, 84:3681-3685.
44. Cherrier M.M., Asthana S., Plymate S., et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001, 57:80-88.
45. Haren M.T., Wittert G.A., Chapman I.M., et al. Effects of oral testosterone undecenoate on visuospatial cognition, mood and quality of like in elderly men with low-normal gonadal status. Maturitas 2005, 50:124-133.
46. Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R., et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008, 299:39-52.
47. Isidori A.M., Giannetta E., Gianfrilli D., et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005, 63:381-394.
48. Boloña E.R., Uraga M.V., Haddad R.M., et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:20-28.
49. Emmelot-Vonk M.H., Verhaar H.J., Nakhai-Pour H.R., et al. Effect of testosterone supplementation on sexual functioning in aging men: a 6-month randomized controlled trial. Int J Impot Res 2009, 21:129-138.
50. Frankle M.A., Eichberg R., Zachariah S.B. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehab 1988, 69:632-633.
51. McNutt R.A., Ferenchick G.S., Kirlin P.C., et al. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 1988, 62:164.
52. Meikle A.W., Arver S., Dobs A.S., et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997, 49:191-196.
53. Behre H.M., Bohmeyer J., Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994, 40:341-349.
54. Cooper C.S., Perry P.J., Sparks A.E., et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998, 159:441-443.
55. Huggins C., Stevens R.E., Hodges C.V. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 43:209-223.
56. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007, 34:555-563.
57. Stattin P., Lumme S., Tenkanen L., et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004, 108:418-424.
58. Barrett-Connor E., Garland C., McPhillips J.B., et al. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990, 50:169-173.
59. Parsons J.K., Carter H.B., Platz E.A., et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005, 14:2257-2260.
60. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006, 296:2351-2361.
61. Bhasin S., Singh A.B., Mac R.P., et al. Managing the risks of prostate disease during testosterone replacement therapy in older men. J Androl 2003, 24:299-311.
62. Liverman C.T., Blazer D.G. Testosterone and aging: clinical research directions. Institute of Medicine 2004, National Academies Press, Washington (DC).
63. Canaris G.J., Manowitz N.R., Mayor G., et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000, 160:526-534.
64. Mariotti S., Barbesino G., Caturegli P., et al. Complex alterations of thyroid function in healthy centenarians. J Clin Endocrinol Metab 1993, 77:1130-1134.
65. Van den Beld A.W., Visser T.J., Feelders R.A., et al. Thyroid hormone concentrations, disease, physical function and mortality in elderly men. J Clin Endocrinol Metab 2005, 90:6403-6409.
66. Magri F., Fioravanti C.M., Vignati G., et al. Thyroid function in old and very old healthy subjects. J Endocrinol Invest 2002, 25:60-63.
67. McDermott M.T., Ridgway C. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Met 2001, 86:4585-4590.
68. Monzani F., Caraccio N., Del Guerra P., et al. Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. Clin Endocrinol 1999, 51:237-242.
69. Joffe R.T., Levitt A.J. Major depression and subclinical (grade 2) hypothyroidism. Psychoneuroendocrinology 1992, 17:215-221.
70. Haggerty J.J., Stern R.A., Mason G.A., et al. Subclinical hypothyroidism: a modifiable risk factor for depression?. Am J Psychiatry 1993, 150:508-510.
71. Baldini I.M., Vita A., Maura M.C., et al. 1997 Psychological and cognitive features in subclinical hypothyroidism. Prog Neurophsychopharmacol Biol Psychiatry 1997, 21:925-935.
72. Danese M.D., Ladenson P.W., Meinert C.L., et al. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000, 85:2993-3001.
73. Monzani F., Caraccio N., Siciliano G., et al. Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. J Clin Endocrinol Metab 1997, 82:3315-3318.
74. Forfar J.C., Wathen C.G., Todd W.T., et al. Left ventricular performance in subclinical hypothyroidism. QJM 1985, 57:857-865.
75. Foldes J., Istvanfy M., Halmagyi M., et al. Hypothyroidism and the heart. Examination of left ventricular function in subclinical hypothyroidism. Acta Med Hung 1987, 44:337-347.
76. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000, 10:665-679.
77. Walsh J.P., Bremner A.P., Bulsara M.K., et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005, 165:2467-2472.
78. Monzani F., Del Guerra P., Caraccio N., et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment. Clin Invest 1993, 71:367-371.
79. Ridgway E.C., Cooper D.S., Walker H., et al. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 1981, 53:1238-1242.
80. Nystrom E., Caidahl K., Fager G., et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol 1988, 29:63-76.
81. Docter R., Krenning E.P., de Jong M., et al. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) 1993, 39:499-518.
82. Peeters R.P., Wouters P.J., Kaptein E., et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003, 88:3202-3211.
83. Iervasi G., Pinitore A., Landi P., et al. Low-T3 syndrome a strong prognostic predictor of death in patients with heart disease. Circulation 2003, 107:708-713.
84. Peeters R.P., Wouters P.J., van Toor H., et al. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005, 90:4559-4565.
85. Chopra I.J., Solomon D.H., Hepner G.W., et al. Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med 1979, 90:905-912.
86. Carrero J.J., Qureshi A.R., Axelsson J., et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007, 262:690-701.
87. Zoccali C., Tripepi G., Cutrupi S., et al. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 2005, 16:2789-2795.
88. Pingitore A., Landi P., Taddei M.C., et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005, 118:132-136.
89. Kozdag G., Ural D., Vural A., et al. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail 2005, 7:113-118.
90. Pingitore A., Galli E., Barison A., et al. Acute effects of triiodothyronine replacement therapy in patients with chronic heart failure and low T3 syndrome: a randomized placebo-controlled study. J Clin Endocrinol Met 2008, 93:1351-1358.
91. Dulchavsky S.A., Kennedy P.R., Geller E.R., et al. T3 preserves respiratory function in sepsis. J Trauma 1991, 31:753-759.
92. Meyer T., Husch M., van den Berg E., et al. Treatment of dopamine-dependent shock with triiodothyronine: preliminary results. Deutsch Med Wochenschr 1979, 104:1711-1714.
93. Hamilton M.A., Stevenson L.W., Fonarow G.C., et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998, 81:443-447.
94. Van Coevorden A., Laurent E., Decoster C., et al. Decreased basal and stimulated thyrotropin secretion in healthy elderly men. J Clin Endocrinol Metab 1989, 69:177-185.
95. Hermann J., Heinen E., Kroll H.J., et al. Thyroid function and thyroid hormone metabolism in elderly people low T3-syndrome in old age. Klin Wochenschr 1981, 59:315-323.
96. Chakraborti S., Chakraborti T., Mandal M., et al. Hypothalamic-pituitary-thyroid axis status of humans during development of ageing process. Clin Chim Acta 1999, 288:137-145.
97. Hesch R.D., Husch M., Kodding R., et al. Treatment of dopamine-dependent shock with triiodothyronine. Endocr Res Commun 1981, 8:299-301.
98. Klemperer J.D., Klein I.L., Ojamaa K., et al. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg 1996, 61:1323-1329.
99. Smidt-Ott U.M., Ascheim D.D. Thyroid hormone and heart failure. Curr Heart Fail Rep 2006, 3:114-119.
100. Abraham G., Milev R., Lawson J.S. T3 augmentation of SSRI resistant depression. J Affect Dis 2006, 91:211-215.
101. Posternak M., Novak S., Stern R., Hennessey J., Joffe R., et al. A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol 2008, 11:15-25.
102. Krotkiewski M., Holm G., Shono N. Small doses of triiodothyronine can change some risk factors associated with abdominal obesity. Int J Obes 1997, 21:922-929.
103. Lowe J., Garrison R., Reichman A., Yellin J., et al. Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clinical Bulletin of Myofascial Therapy 1997, 2:31-58.
104. Yellin B.A., Reichman A.J., Lowe J.C., et al. The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. The Metabolic Treatment of Fibromyalgia 2000, McDowell Publishing, Old Fort (NC).
105. Tanis B.C., Westendorp R.G.J., Smelt A.H.M. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a re-analysis of intervention studies. Clin Endocrinol 1996, 44:643-649.